Search

Chamaecyparis obtusa whole

Neocartilage

Neocartilage, a novel cartilage regeneration treatment. Neocartilage is generated from juvenile rather than adult chondrocytes. … Neocartilage is the only scaffold-free living cartilage graft on the market.

Silibinin

Silibinin is presented as a mixture of two diastereomers, silybin A and silybin B, which are found in an approximately equimolar ratio. … Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin

NN344

NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. … The product is intended for basal insulin treatment of diabetes mellitus.

Sarracenia Purpurea

It is widely distributed across North America and has been used as a traditional medicinal herb in many aboriginal communities [A32509, A32510]. … _Sarracenia purpurea_, commonly known as the purple pitcher plant, northern pitcher plant, turtle socks, or side-saddle flower, is a perennial carnivorous plant in the family _Sarraceniaceae_.

PH-284

Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. … PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients.

Miocamycin

Miocamycin is a macrolide type antimicrobial [A176170]. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737]. … It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections

Moricizine

An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

AZD 3355

AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

Pegpleranib